PTC Therapeutics Inc Splicing Deep Dive Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the PTC Splicing Deep Dive Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Alex Kane, Executive Director of Investor Relations. Thank you. Please go ahead, sir.
Thank you, and good morning, everyone. Happy Friday. Thank you for joining us today for this second webinar in our deep dive series focused on the splicing platform. With me on today's call is our Chief Executive Officer, Stuart Peltz; and our Chief Scientific Officer, Mark Pykett. We're also pleased to have on the call 3 key members of the research team who have 30-plus years of combined experience at PTC, largely focused on RNA biology. With us on the call is Nikolai Naryshkin, our VP of External Innovation; Chris Trotta, our VP of Biology; and Matt Woll, our VP of Chemistry.
Before we start, let me remind you that today's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |